Apoptosis is one of the fundamental processes in all metazoans. Deregulation of apoptosis causes abnormal development and various human diseases, such as cancer, neuronal and immunological diseases. It is widely believed that mitochondrion is an integrator of the apoptotic machinery and caspases are the central executioners of apoptosis (Green and Reed, 1999; Hengartner, 2000; Strasser et al., 2000; Wang, 2001; Hunot and Flavell, 2001) . However, numerous studies have demonstrated that apoptosis can occur in a caspase-independent process (Kuida et al., 1996; Amarante-Mendes et al., 1998; Cecconi et al., 1998; Hakem et al., 1998; Kuida et al., 1998; Yoshida et al., 1998; Haraguchi et al., 2000; Li et al., 2000; Bidere and Senik, 2001) . One of the molecules that have been implicated in caspase-independent apoptosis is AIF, an oxidoreductase localized in the intermembrane space of mitochondria (Susin et al., 1999; Daugas et al., 2000; Joza et al., 2001; Loeffler et al., 2001; Miramar et al., 2001) . Upon stimulation by death signals, AIF translocates from the mitochondria to the nucleus and causes chromosome condensation and large-scale DNA fragmentation (Susin et al., 1999; Daugas et al., 2000) . These effects are independent of caspases and the oxidoreductase activity of AIF (Susin et al., 1999; Daugas et al., 2000; Joza et al., 2001; Loeffler et al., 2001; Miramar et al., 2001) .
We and others have identified an AIF homologous protein called AMID or PRG3 (Ohiroa et al., 2002; Wu et al., 2002) . AMID is associated with the outer membrane of mitochondria and induces caspase-independent apoptosis (Wu et al., 2002) . It has also been shown that human AMID gene is transcriptionally induced by p53 and a consensus p53-responsive element is identified in intron 5 (Ohiroa et al., 2002) . Using a p53-inducible cell line D-p53-A2 (Provided by Dr Bert Vogelstein), we confirmed that human AMID mRNA is induced by p53 (Figure 1a ). To further investigate the regulatory mechanisms of human AMID mRNA expression, we cloned a 1.3 kb fragment of the 5 0 upstream regulatory region of human AMID gene. Sequence analysis indicated that human AMID mRNA promoter does not contain a typical TATA box, but contains a consensus transcription initiator (Inr) sequence (PyPyA( þ 1)NT/APyPy (Py ¼ pyrimidine)) (Smale, 1997) at the junction of the putative promoter and 5 0 end of the cDNA (data not shown). A previous study identified a consensus p53-responsive element in intron 5 of human AMID gene (Ohiroa et al., 2002) . This study failed to identify consensus p53-responsive element(s) in the promoter of human AMID gene (Ohiroa et al., 2002) . We cloned the 1.3 kb human AMID gene promoter (À1333 to þ 8, referred as AMID-P1) into a luciferase reporter plasmid and examined whether this promoter can be activated by p53. We transfected 293 cells with the AMID-P1 luciferase reporter plasmid and a mammalian expression plasmid for p53 or empty control plasmid. Reporter gene assay indicated that p53 potently activated human AMID promoter (Figure 1b) . To determine whether endogenous p53 can also activate human AMID promoter, we transfected 293 cells with the reporter plasmid and then treated the cells with DNA damage and p53-inducing drug 5-fluorouracil. The reporter gene assay indicated that 5-fluorouracil also activated the human AMID gene promoter (Figure 1b) .
To determine whether p53 can bind to AMID promoter, we performed chromatin immunoprecipitation (ChIP) experiments. To do this, we transfected 293 cells with a mammalian expression plasmid for HAtagged p53 or empty control plasmid. Total cell lysates were immunoprecipitated with or without a monoclonal anti-HA antibody. The pulled-down DNAs were amplified by PCR with primers corresponding to the human AMID promoter sequence. The result indicated that p53 could bind to the promoter of human AMID ( Figure 1c ). In these experiments, p53 did not bind to the suggested p53 responsive element in intron 5 of human AMID gene (Ohiroa et al., 2002) , but could bind to the well-established p53 responsive elements in the promoter of human MDM2 gene. Taken together, these results suggest that human AMID promoter is transcriptionally activated by p53.
Since human AMID promoter is activated by p53, we attempted to identify p53-binding element(s) in the promoter. Consistent with the previous study (Ohiroa et al., 2002) , we failed to identify consensus p53-responsive elements using TransFac software program (http://transfac.gbf.de). We reasoned that the p53-responsive elements in human AMID promoter were not sufficient conserved with the consensus p53 response element to be identified by the program. To map the p53-responsive elements in human AMID promoter, we made three deletion mutants of the 1.3 kb human AMID promoter, including AMID-P2 (À1194 to þ 8), AMID-P3 (À613 to þ 8), and AMID-p4 (À442 to þ 8) (Figure 2a ). These mutants were cloned into the pGL3-basic luciferase reporter plasmid, and reporter gene assay was performed. The results indicated that p53-induced activation of AMID-P3 was dramatically reduced in comparison to AMID-P1, while p53 did not activate AMID-P4 at all (Figure 2c ). p53-induced AMID-P2 activity was relatively lower than AMID-P1. As AMID-P2 had lower basal activity, p53 inducibility for AMID-P2 was similar with AMID-P1 (data not shown). Based on these data, we concluded that the p53-responsive elements in AMID promoter are located between À1192 and À442.
We then aligned the sequence of the À1192 to À42 fragment of human AMID promoter with the consensus p53-responsive element and the specific p53-responsive elements found in the promoters of the p53-downstream genes p21 and MDM2 (el-Deiry et al., 1993; Wu et al., 1993) . This analysis identified two motifs in human AMID promoter, site A (À589 to À556) and site B (À675 to À644), which are potential p53-responsive In total, 293 cells were transfected with the B1.3 kb human AMID promoter luciferase reporter plasmid (AMID-P1) together with an expression plasmid for p53, or 293 cells were co-transfected with AMID-P1 and an empty control plasmid and immediately treated with 5-fluorouracil or left untreated. At 16 h after transfection, luciferase reporter assays were performed. In these experiments, pRL-SV40 (a constitutive Renilla luciferase reporter plasmid) was added to all transfections and the firefly luciferase activities were normalized based on the Renilla luciferase activities. (c) p53 binds to the promoter of human AMID gene. In all, 293 cells were transfected with an expression plasmid for HA-tagged p53 or an empty control plasmid. At 18 h after transfection, ChIP assay was performed as described (Shang et al., 2000) with mouse monoclonal anti-HA antibody and the following primers. (Figure 2b ). To determine whether these two motifs are involved in p53-induced activation of human AMID promoter, we performed deletion mutagenesis and reporter gene assays. As shown in Figure 3 , deletion of site A dramatically reduced p53-induced AMID-P1 and AMID-P2 activation. Deletion of site 1 completely abolished p53-induced activation of AMID-P3. In addition, deletion of site 2 also reduced p53-induced activation of AMID-P1, while the simultaneous deletion of both sites completely abolished p53-induced activation of AMID-P1 (Figure 3 ). These data suggest that both sites are important for p53-induced activation of human AMID promoter. Since deletion of site A had more dramatic effect than that of site B, site A may have a larger role than site B in p53-induced activation of human AMID promoter.
Our ChIP experiments failed to demonstrate p53 binding to the putative p53 response element in intron 5 of human AMID gene (Ohiroa et al., 2002) . In the experiments by Ohiroa et al. (2002) , the potential p53 responsive element was identified by sequence scanning with the consensus p53 bind site, and was fused to a minimal promoter for co-transfection studies. This kind of approach may lead to errors. For example, a site identified from CDC25C gene, when fused to a minimal promoter, could lead to activation by p53 (ResnickSilverman et al., 1998) , but in its natural promoter context could not be activated by p53 (Krause et al., 2001) .
Since AMID induces apoptosis and AMID gene is transcriptionally induced by the tumor suppressor p53, we investigated whether expression of AMID is regulated in tumors. To do this, we used a human matched tumor/normal expression array blot purchased from Clontech Inc. This blot contains cDNA samples originating from 68 individually matched tumor and para-tumor normal tissues. This blot was hybridized with a 32 P-labeled human AMID cDNA probe. The results indicated that AMID mRNA expression was downregulated in most tumors compared to their matched para-tumor normal tissues (Figure 4 ). In this In our previous studies, we found that AMID expression could be detected easily in some colon cancer cell lines (Wu et al., 2002) . The simplest explanation for these observations is that some cancer cells have upregulated expression of a mutated and dominantnegative AMID protein, as is the case for p53 in many tumors (Levine et al., 1991; Lutzker and Levine, 1996; Levine, 1997) . p53 is the most studied tumor suppressor gene and mutation of p53 has been implicated in a majority of tumors (Levine et al., 1991; Lutzker and Levine, 1996; Levine, 1997; Vogelstein et al., 2000; Oren, 2003) . p53 is induced by damaging DNA and it antagonizes cell transformation through inducing apoptosis, growth arrest and senescence (Levine et al., 1991; Lutzker and Levine, 1996; Levine, 1997; Vogelstein et al., 2000; Oren, 2003) . p53's cellular effects are mediated through its transcriptional activation of genes involved in apoptosis, growth arrest and senescence. For example, induction of p21 by p53 causes growth arrest and senescence (el-Deiry et al., 1993) . p53 induces apoptosis through induction of a set of apoptotic genes, such as Apaf-1, NOXA, Bax, BAD, DR5 and PUMA (Levine et al., 1991; Lutzker and Levine, 1996; Levine, 1997; Vogelstein et al., 2000; Oren, 2003) . In this report, we have identified AMID as a novel p53-inducible gene. We have characterized the p53-responsive elements in human AMID gene promoter. Expression array analysis suggests that AMID is downregulated in most examined tumors. Our findings suggest that AMID is a novel p53-downstream effecter involved in regulation of tumorigenesis. 
